Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2007.437 | Quality of Life Measurements in Chinese Women with Pelvic Floor Disorders - Validation Study of Pelvic Floor Distress Inventory (PEDI) and Pelvic Floor Impact Questionnaire (PFIQ) | Dr. Chan Shing Chee, Symphorosa |
| 2010.519 | Prospective, Randomized, Double-blind Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients | Dr Chan Shu Yin Eddie |
| 2010.457 | An Open-label Phase Ii Study of TK1258 as Neo-adjuvant Therapy in Patient with Muscle-invasive Bladder Cancer | Dr Chan Shu Yin Eddie |
| 2013.302 | Clinical study to evaluate the efficacy and safety of autologous fibrin sealant in laparoscopic / robotic radical cystectomy | Dr Chan Shu Yin Eddie |
| 2013.223 | A MULTICENTRE STUDY FOR THE EVALUATION OF EFFICACY AND SAFETY OF BUPRENORPHINE TRANSDERMAL PATCH (NORSPANｮ OR SOVENORｮ TRANSDERMAL PATCH)IN PATIENTS WITH NON-MALIGNANT PAIN OF MODERATE TO SEVERE INTENSITY DUE TO OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, LOWER BACK PAIN AND JOINT / MUSCLE PAIN, WHEN AN OPIOID IS NECESSARY FOR OBTAINING ADEQUATE ANALGESIA | Dr. CHAN Simon KC |
| 2013.666 | A Randomized - Control Multi-Centers Study on The Safety and Effectiveness of Peri-Operative Transfusion Trigger Score (POTTS) | Dr Chan Simon Kin Cheong |
| 2016.616 | A multi-center, open-label, single arm, prospective study evaluating the sealing performance of the Shiley™ Laryngeal Mask in a post market clinical follow up (PMCF) |
Dr. CHAN Simon Kin Cheong 陳建昌 |
| 2009.336 | Efficacy of TTS-fentanyl given after weak opioid in patients with cancer related pain without stabilization phase: An open label study | Dr Chan Simon Kin Cheong |
| 2024.172 | Development of virtual reality-enhanced intervention for adults undergoing elective surgery: a qualitative study | Mr. CHAN Sin Lun |
| 2019.273 | Development, implementation and evaluation of a clinical practice guideline for care of preterm infants receiving the non-invasive ventilation: A before and after study |
Ms. CHAN Sin Yee 陳倩儀 |
| 2014.598 | Postural stability in elderly with toe deformities: a case-control study | Miss Chan Som Yu |
| 2023.376 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 2: Biliary Tract Cancer (BTC) | Prof. CHAN Stephan Lam |
| 2024.150 | Establishment of New Territories East Cluster Pancreatic Cancer Database | Prof. CHAN Stephen |
| 2017.532 | A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA) |
Dr. CHAN Stephen 陳林醫生 |
| 2014.103 | The effect of metformin on the outcome of type II diabetic patients with hepatocellular carcinoma | Dr. CHAN Stephen |
| 2009.433 | Evaluation of enlarged regional lymph nodes with endoscopic ultrasound in unresectable hepatocellular carcinoma | Dr Chan Stephen L. |
| 2009.296 | Detection of circulating tumor cells in advanced hepatocellular carcinoma undergoing systemic therapy: a pilot study | Prof. Chan Stephen L. |
| 2009.441 | Prospective validation of the Chinese University Prognostic Index and Comparison with AJCC TNM, BCLC, CLIP and Okuda's staging system for hepatocellular carcinoma in Asian polulation | Prof. Chan Stephen L. |
| 2009.086 | Prospective Study of Reginal Lymph Node Staging by Endoscopic Ultrasound Guided Biopsy in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization | Dr Chan Stephen L. |
| 2017.008 | Prospective study on the inflammation environment of hepatocellular carcinoma as signified by the mIBI in patients treated with systemic treatment and immunotherapeutics |
Dr. CHAN Stephen L. 陳林 |
| 2017.501 | A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SECOND-LINE SYSTEMIC THERAPY |
Dr. CHAN Stephen L. 陳林醫生 |
| 2022.202 | Real world analysis of sequencing of systemic treatment in hepatocellular carcinoma |
Prof. CHAN Stephen L. 陳林 |
| 2013.237 | A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma | Dr. CHAN Stephen L. |
| 2014.071 | Detection and quantification of mutations in KIT or PDGFRA with droplet digital PCR in plasma of patients with Gastrointestinal Stromal Tumor (GIST) | Dr. CHAN Stephen L. |
| 2014.091 | Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II study | Dr. CHAN Stephen L. |
| 2019.150 | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) |
Dr. CHAN Stephen L. 陳林醫生 |
| 2018.396 | A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation |
Dr. CHAN Stephen L. 陳林醫生 |
| 2015.090 | Development of clinical model to predict the capecitabine-related toxicity in the Chinese population of colorectal cancer |
Dr. CHAN Stephen L. 陳林 |
| 2016.074 | A proof-of-concept phase II clinical trial on the use everolimus in TSC2-hull/low hepatocellular carcinoma |
Dr. CHAN Stephen L. 陳林 |
| 2014.535 | A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression | Prof. CHAN Stephen Lam |
| 2016.393 | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2017.661 | PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2016.172 | A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2015.361 | Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib |
Dr. CHAN Stephen Lam 陳林 |
| 2017.465 | A clinical trial of pembrolizumab in patients with hepatitis B virus-related hepatocellular carcinoma, with parallel study on baseline and serial change in the immune environment |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.049 | A phase Ib study of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.653 | A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2016.016 | A phase III, Open-label, Randomized Study of the Combination Therapy with NC-6004 and Gemcitabine versus Gemcitabine Alone in Patients with Locally Advanced or Metastatic Pancreatic Cancer |
Dr. CHAN Stephen Lam 陳林 |
| 2016.730 | A study on thromboembolism in pancreatic cancer patients |
Dr. CHAN Stephen Lam 陳林 |
| 2015.072 | A Phase 3, Randomized, Double-blind,Placebo-controlled Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase | Dr. CHAN Stephen Lam |
| 2014.404 | A Randomized Phase 2 Study of LY2157299 versus LY2157299 – Sorafenib Combination versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2016.262 | A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2015.581 | A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.526 | A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemcitabine in combination with placebo, followed as second line treatment by masitinib in combination with Folfiri 3 versus placebo in combination with Folfiri 3 in the treatment of patients with non resectable locally advanced or metastatic pancreatic cancer | Prof. CHAN Stephen Lam |
| 2019.259 | Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2020.625 | A PHASE II, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIARY TRACT CANCER |
Dr. CHAN Stephen Lam 陳林 醫生 |
| 2019.474 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION |
Prof. CHAN Stephen Lam 陳林 醫生 |
| 2019.694 | A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to checkpoint inhibitors |
Dr. CHAN Stephen Lam 陳林 |
| 2019.387 | A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination with Brivanib Alaninate (ZL-2301) in Patients with Advanced Liver Cancer | Dr. CHAN Stephen Lam |
| 2020.568 | FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements |
Dr. CHAN Stephen Lam 陳林 |
Page 66 of 254.